Literature DB >> 32251618

Current Drugs with Potential for Treatment of COVID-19: A Literature Review.

.   

Abstract

PURPOSE: SARS-CoV-2 first emerged in China in December 2019 and rapidly spread worldwide. No vaccine or approved drug is available to eradicate the virus, however, some drugs that are indicated for other afflictions seems to be potentially beneficial to treat the infection albeit without unequivocal evidence.   The aim of this article is to review the published background on the effectiveness of these drugs against COVID-19
Methods: A thorough literature search was conducted on recently published studies which have published between January 1 to March 25, 2020. PubMed, Google Scholar and Science Direct databases were searched
Results: A total 22 articles were found eligible. 8 discuss about treatment outcomes from their applied drugs during treatment of COVID-19 patients, 4 report laboratory tests, one report animal trial and other 9 articles discuss recommendations and suggestions based on the treatment process and clinical outcomes of other diseases such as malaria, ebola, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). The data and/or recommendations are categorized in 4 classes: (a) anti-viral and anti-inflammatory drugs, (b) anti-malaria drugs, (c) traditional Chinese drugs and (d) other treatments/drugs.
CONCLUSION: All examined treatments, although potentiality effective against COVID-19, need either appropriate drug development or clinical trial to be suitable for clinical use.

Entities:  

Year:  2020        PMID: 32251618     DOI: 10.18433/jpps31002

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  29 in total

1.  Should all COVID-19 patients be approached in the same way?

Authors:  Caio Julio Cesar Dos Santos Fernandes
Journal:  J Bras Pneumol       Date:  2020-07-20       Impact factor: 2.624

Review 2.  Sex differences in COVID-19: the role of androgens in disease severity and progression.

Authors:  Mohamed S Mohamed; Thiago C Moulin; Helgi B Schiöth
Journal:  Endocrine       Date:  2020-11-11       Impact factor: 3.633

Review 3.  Flavonoids as potential phytotherapeutics to combat cytokine storm in SARS-CoV-2.

Authors:  Abhishek Gour; Diksha Manhas; Swarnendu Bag; Bapi Gorain; Utpal Nandi
Journal:  Phytother Res       Date:  2021-03-30       Impact factor: 6.388

4.  Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation.

Authors:  Andrea Mortara; Simone Mazzetti; Davide Margonato; Pietro Delfino; Chiara Bersano; Francesco Catagnano; Marinella Lauriola; Paolo Grosso; Gianluca Perseghin; Giovanbattista Ippoliti
Journal:  Clin Transl Sci       Date:  2021-01-27       Impact factor: 4.689

Review 5.  The SARS-Coronavirus Infection Cycle: A Survey of Viral Membrane Proteins, Their Functional Interactions and Pathogenesis.

Authors:  Nicholas A Wong; Milton H Saier
Journal:  Int J Mol Sci       Date:  2021-01-28       Impact factor: 6.208

Review 6.  Innovative highlights of clinical drug trial design.

Authors:  Daohong Chen; Eric Yining Qi
Journal:  Transl Res       Date:  2020-06-03       Impact factor: 7.012

7.  Screening of Chloroquine, Hydroxychloroquine and its derivatives for their binding affinity to multiple SARS-CoV-2 protein drug targets.

Authors:  Mallikarjuna Nimgampalle; Vasudharani Devanathan; Ambrish Saxena
Journal:  J Biomol Struct Dyn       Date:  2020-06-24

Review 8.  Emergent Drug and Nutrition Interactions in COVID-19: A Comprehensive Narrative Review.

Authors:  Duygu Ağagündüz; Menşure Nur Çelik; Merve Esra Çıtar Dazıroğlu; Raffaele Capasso
Journal:  Nutrients       Date:  2021-05-04       Impact factor: 5.717

Review 9.  High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects.

Authors:  Xiaosheng Liu; Wei Cao; Taisheng Li
Journal:  Front Immunol       Date:  2020-07-14       Impact factor: 7.561

10.  Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover.

Authors:  Annarosa Soresina; Daniele Moratto; Marco Chiarini; Ciro Paolillo; Giulia Baresi; Emanuele Focà; Michela Bezzi; Barbara Baronio; Mauro Giacomelli; Raffaele Badolato
Journal:  Pediatr Allergy Immunol       Date:  2020-05-19       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.